{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:02:28Z","timestamp":1788346948304,"version":"build-2803163510"},"reference-count":158,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The rubric of immune-related (ir) diabetes mellitus (DM) (irDM) encompasses various hyperglycemic disorders related to immune checkpoint inhibitors (ICPis). Beyond sharing similarities with conventional DM, irDM is a distinct, yet important, entity. The present narrative review provides a comprehensive overview of the literature regarding irDM published in major databases from January 2018 until January 2023. Initially considered rare, irDM is increasingly being reported. To advance the knowledge of irDM, the present review suggests a concerted vision comprising two intertwined aspects: a scientific-centered and a patient-centered view. The scientific-centered aspect addresses the pathophysiology of irDM, integrating: (i) ICPi-induced pancreatic islet autoimmunity in genetically predisposed patients; (ii) altered gut microbiome; (iii) involvement of exocrine pancreas; (iv) immune-related acquired generalized lipodystrophy. The patient-centered aspect is both nurtured by and nurturing the four pillars of the scientific-centered aspect: awareness, diagnosis, treatment, and monitoring of irDM. The path forward is a multidisciplinary initiative towards: (i) improved characterization of the epidemiological, clinical, and immunological profile of irDM; (ii) standardization of reporting, management, and surveillance protocols for irDM leveraging global registries; (iii) patient stratification according to personalized risk for irDM; (iv) new treatments for irDM; and (v) uncoupling ICPi efficacy from immunotoxicity.<\/jats:p>","DOI":"10.3390\/ijms24087630","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:48:11Z","timestamp":1682052491000},"page":"7630","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors"],"prefix":"10.3390","volume":"24","author":[{"given":"Maria V.","family":"Deligiorgi","sequence":"first","affiliation":[{"name":"Department of Pharmacology-Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-9780","authenticated-orcid":false,"given":"Dimitrios T.","family":"Trafalis","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Clinical Pharmacology Unit, Faculty of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41422-020-0277-x","article-title":"The yin and yang of co-inhibitory receptors: Toward anti-tumor immunity without autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"key":"ref_5","unstructured":"Cancer Research Institute (CRI) (2023, January 15). FDA Approval Timeline of Active Immunotherapies. Available online: https:\/\/www.cancerresearch.org\/fda-approval-timeline-of-active-immunotherapies."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities from Disproportionality Analysis of the FDA Adverse Event Reporting System","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"Andreescu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/imt-2019-0132","article-title":"Endocrine adverse events related with immune checkpoint inhibitors: An update for clinicians","volume":"12","author":"Deligiorgi","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: A novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"764138","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). 2. Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes\u20142020. Diabetes Care, 43, S14\u2013S31.","DOI":"10.2337\/dc20-S002"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MOG.0000000000000873","article-title":"Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis)","volume":"38","author":"Abreo","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Tang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"622442","DOI":"10.3389\/fimmu.2020.622442","article-title":"B Cells in Patients with Melanoma: Implications for Treatment with Checkpoint Inhibitor Antibodies","volume":"11","author":"Willsmore","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"790386","DOI":"10.3389\/fcell.2021.790386","article-title":"Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1","volume":"9","author":"Mor","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00125-022-05778-3","article-title":"Precision medicine in type 1 diabetes","volume":"65","author":"Carr","year":"2022","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mota Reyes, C., Demir, E., \u00c7ifciba\u015f\u0131, K., Istvanffy, R., Friess, H., and Demir, I.E. (2022). Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Cancers, 14.","DOI":"10.3390\/cancers14194582"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.3389\/fimmu.2019.03100","article-title":"Treg Heterogeneity, Function, and Homeostasis","volume":"10","author":"Shevyrev","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fimmu.2019.00019","article-title":"FOXP3+ Regulatory T Cell Compartment Is Altered in Children with Newly Diagnosed Type 1 Diabetes but Not in Autoantibody-Positive at-Risk Children","volume":"10","author":"Viisanen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2107208118","DOI":"10.1073\/pnas.2107208118","article-title":"Human islet T cells are highly reactive to preproinsulin in type 1 diabetes","volume":"118","author":"Anderson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s40425-019-0628-7","article-title":"PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8(+) T lymphocytes","volume":"7","author":"Ogando","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"926714","DOI":"10.3389\/fimmu.2022.926714","article-title":"The Road Less Taken: Less Appreciated Pathways for Manipulating CD8+ T Cell Exhaustion","volume":"13","author":"Pichler","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.molcel.2020.02.013","article-title":"PD-1: A Driver or Passenger of T Cell Exhaustion?","volume":"77","author":"He","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"977394","DOI":"10.3389\/fimmu.2022.977394","article-title":"T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MED.0000000000000488","article-title":"Enforcing the checkpoints: Harnessing T-cell exhaustion for therapy of T1D","volume":"26","author":"Linsley","year":"2019","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"Ebiomedicine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","article-title":"Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes","volume":"8","author":"Osum","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/imcb.12444","article-title":"Harnessing CD8+ T-cell exhaustion to treat type 1 diabetes","volume":"99","author":"Kwong","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41574-020-0330-3","article-title":"A predictive CD8+ T cell phenotype for T1DM progression","volume":"16","author":"Wong","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1172\/JCI126595","article-title":"Autoreactive Cd8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression","volume":"130","author":"Wiedeman","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00592-021-01711-z","article-title":"Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes","volume":"58","author":"Shan","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Pellegrino, M., Crin\u00f2, A., Rosado, M.M., and Fierabracci, A. (2019). Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210839"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2019-0806","article-title":"Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes","volume":"25","author":"Zagouras","year":"2020","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc18-2518","article-title":"T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors","volume":"42","author":"Yoneda","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mourad, D., Azar, N.S., Eid, A.A., and Azar, S.T. (2021). Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042093"},{"key":"ref_48","first-page":"78","article-title":"Checkpoint inhibitor develops histological autoimmune pancreatitis like type 1 diabetes. A case report","volume":"10","author":"Mazzucato","year":"2020","journal-title":"MOJ Clin. Med. Case Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/pedi.12597","article-title":"Genetics of type 1 diabetes","volume":"19","author":"Redondo","year":"2018","journal-title":"Pediatr. Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8821","DOI":"10.1038\/s41598-021-86229-8","article-title":"Nine residues in HLA-DQ molecules determine with susceptibility and resistance to type 1 diabetes among young children in Sweden","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"683946","DOI":"10.3389\/fgene.2021.683946","article-title":"Type 1 Diabetes and the HLA Region: Genetic Association Besides Classical HLA Class II Genes","volume":"12","author":"Sticht","year":"2021","journal-title":"Front. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct from Type 1 Diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.18632\/oncotarget.27665","article-title":"Rapid Onset Type 1 Diabetes with Anti-PD-1 Directed Therapy","volume":"11","author":"Yun","year":"2020","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: A systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","article-title":"Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: Type 1 Diabetes Variant or New Clinical Entity?","volume":"22","author":"Salvagni","year":"2021","journal-title":"Rev. Lit. Rev. Endocr. Metab. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/DMSO.S295847","article-title":"Islet Autoantibodies in the Patients with Sjogren\u2019s Syndrome and Thyroid Disease and Risk of Progression to Latent Autoimmune Diabetes in Adults: A Case Series","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00125-022-05843-x","article-title":"Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering","volume":"66","author":"Mistry","year":"2022","journal-title":"Diabetologia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00125-020-05176-7","article-title":"Presumption of innocence for beta cells: Why are they vulnerable autoimmune targets in type 1 diabetes?","volume":"63","author":"Mallone","year":"2020","journal-title":"Diabetologia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.25122\/jml-2021-0387","article-title":"Immunological markers in type 1 diabetes mellitus in Thi-Qar province, southern Iraq","volume":"15","author":"Hamadi","year":"2022","journal-title":"J. Med. Life"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review","volume":"181","author":"Pen","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune Checkpoint Inhibitors: An Emerging Cause of Insulin-Dependent Diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin. Diabetes Endocrinol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e25795","DOI":"10.1097\/MD.0000000000025795","article-title":"Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review","volume":"100","author":"Huang","year":"2021","journal-title":"Medicine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"844","DOI":"10.4049\/jimmunol.1801535","article-title":"Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes","volume":"203","author":"Martinov","year":"2019","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41232-021-00164-9","article-title":"Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases","volume":"41","author":"Hao","year":"2021","journal-title":"Inflamm. Regen."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1210\/jc.2019-00093","article-title":"Follicular regulatory T cells are associated with \u03b2-cell autoimmunity and the development of type 1 diabetes","volume":"104","author":"Xu","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"679909","DOI":"10.3389\/fimmu.2021.679909","article-title":"T Follicular Regulatory Cells: Choreographers of Productive Germinal Center Responses","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Matija\u0161i\u0107, M., Me\u0161trovi\u0107, T., Paljetak, H.\u010c., Peri\u0107, M., Bare\u0161i\u0107, A., and Verbanac, D. (2020). Gut Microbiota beyond Bacteria-Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082668"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"814269","DOI":"10.3389\/fnut.2022.814269","article-title":"Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc21-1656","article-title":"The Gut Microbiome of Adults with Type 1 Diabetes and Its Association with the Host Glycemic Control","volume":"45","author":"Shilo","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc21-2225","article-title":"The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates with Glycemic Control and Disease-Related Complications","volume":"45","author":"Gacesa","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12964-020-00599-6","article-title":"Intestinal microbiota: A new force in cancer immunotherapy","volume":"18","author":"Dai","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"929","DOI":"10.5306\/wjco.v13.i11.929","article-title":"Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review","volume":"13","author":"Oey","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Oh, B., Boyle, F., Pavlakis, N., Clarke, S., Eade, T., Hruby, G., Lamoury, G., Carroll, S., Morgia, M., and Kneebone, A. (2021). The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. Cancers, 13.","DOI":"10.3390\/cancers13194824"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez, M.S., Manzano, A., Olivar, L.C., Nava, M., Salazar, J., D\u2019Marco, L., Ortiz, R., Chac\u00edn, M., Guerrero-Wyss, M., and Cabrera de Bravo, M. (2021). The Role of the \u03b1 Cell in the Pathogenesis of Diabetes: A World beyond the Mirror. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179504"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2337\/db20-0995","article-title":"Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size","volume":"70","author":"Ross","year":"2021","journal-title":"Diabetes"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"107974","DOI":"10.1016\/j.diabres.2019.107974","article-title":"Low serum amylase, lipase, and trypsin as biomarkers of metabolic disorders: A systematic review and meta-analysis","volume":"159","author":"Ko","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: Description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2337\/dc17-2243","article-title":"Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?","volume":"41","author":"Marchand","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Nakano, R., Shiomi, H., Fujiwara, A., Yoshihara, K., Yoshioka, R., Kawata, S., Ota, S., Yuri, Y., Takashima, T., and Aizawa, N. (2022). Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthcare, 10.","DOI":"10.3390\/healthcare10050763"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1027323","DOI":"10.1155\/2018\/1027323","article-title":"Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis","volume":"2018","author":"Su","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"955701","DOI":"10.3389\/fphar.2022.955701","article-title":"Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41572-020-0181-1","article-title":"HIV and antiretroviral therapy-related fat alterations","volume":"6","author":"Koethe","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired Lipodystrophy Associated with Nivolumab in a Patient With Advanced Renal Cell Carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin. Case Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/db21-1172","article-title":"Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy","volume":"72","author":"Vazquez","year":"2023","journal-title":"Diabetes"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.21037\/atm.2018.10.71","article-title":"Post-immunotherapy new onset diabetes (PINOD)-under-recognized etiology, unexplored presentation","volume":"6","author":"Kalra","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens a Systematic Review and Meta-Analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: A comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3389\/fphar.2019.01453","article-title":"Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies","volume":"10","author":"Lu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS","volume":"9","author":"Ji","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc21-2213","article-title":"Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes","volume":"45","author":"Chen","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","article-title":"Checkpoint inhibitor-induced insulin-dependent diabetes: An emerging syndrome","volume":"7","author":"Perdigoto","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_102","first-page":"4508633","article-title":"Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice","volume":"2022","author":"Bellido","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.2337\/dc20-0609","article-title":"Immune Checkpoint Inhibitor\u2013Associated Diabetes: A Single-Institution Experience","volume":"43","author":"Byun","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101473","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National Comprehensive Cancer Network (2018). Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e14788","DOI":"10.1111\/dme.14788","article-title":"The management of diabetic ketoacidosis in adults\u2014An updated guideline from the Joint British Diabetes Society for Inpatient Care","volume":"39","author":"Dhatariya","year":"2022","journal-title":"Diabet. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/sjmms.sjmms_478_19","article-title":"Management of Diabetic Ketoacidosis in Adults: A Narrative Review","volume":"8","author":"Eledrisi","year":"2020","journal-title":"Saudi J. Med. Med. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/dmrr.1236","article-title":"Fulminant type 1 diabetes\u2014An important subtype in East Asia","volume":"27","author":"Imagawa","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.3748\/wjg.v27.i30.4939","article-title":"Diabetes and pancreatic cancer: Exploring the two-way traffic","volume":"27","author":"Roy","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"730038","DOI":"10.3389\/fonc.2021.730038","article-title":"Type 2 Diabetes Mellitus Intersects with Pancreatic Cancer Diagnosis and Development","volume":"11","author":"Duan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4239\/wjd.v12.i7.1010","article-title":"Current cancer therapies and their influence on glucose control","volume":"12","author":"Yim","year":"2021","journal-title":"World J. Diabetes."},{"key":"ref_117","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). Endotext, MDText.com, Inc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/COC.0000000000000612","article-title":"Determining the Impact of a Cancer Diagnosis on Diabetes Management: A Systematic Literature Review","volume":"42","author":"Pinheiro","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). Standards of Medical Care in Diabetes\u20142020; Abridged for Primary Care Providers. Clin. Diabetes, 38, 10\u201338.","DOI":"10.2337\/cd20-as01"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jdi.13927","article-title":"Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report","volume":"14","author":"Okubo","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e001622","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u2265 2 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Haratani, K., Hayashi, H., and Nakagawa, K. (2020). Association of immune-related adverse events with immune checkpoint inhibitor efficacy: Real or imaginary?. BMC Med., 18.","DOI":"10.1186\/s12916-020-01583-0"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1634\/theoncologist.2019-0299","article-title":"Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer","volume":"25","author":"Akamatsu","year":"2020","journal-title":"Oncologist"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"631949","DOI":"10.3389\/fonc.2021.631949","article-title":"Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): A case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.2147\/DMSO.S375023","article-title":"Association of Cytotoxic T-Lymphocyte Antigen-4 Gene Polymorphism with Type 1 Diabetes Mellitus: In silico Analysis of Biological Features of CTLA-4 Protein on Ethiopian Population","volume":"15","author":"Ebrahim","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"10074","DOI":"10.1038\/s41598-018-28423-9","article-title":"CTLA-4 +49\u2009G\/A, a functional T1D risk SNP, affects CTLA-4 level in Treg subsets and IA-2A positivity, but not beta-cell function","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.2147\/DMSO.S374451","article-title":"Association of CLTA-4 Gene Polymorphisms with Diabetes Mellitus: A Study Based on the Han Population of Northern China","volume":"15","author":"Ren","year":"2022","journal-title":"Diabetes Metab. Syndr Obes."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Mart\u00edn, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176275"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MOG.0000000000000756","article-title":"Diabetes in chronic pancreatitis: Risk factors and natural history","volume":"37","author":"Goodarzi","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.4049\/jimmunol.1900264","article-title":"Report on the 2018 Cancer, Autoimmunity, and Immunology Conference","volume":"202","author":"Curran","year":"2019","journal-title":"J. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s40425-019-0799-2","article-title":"Peripheral immune-based biomarkers in cancer immunotherapy: Can we realize their predictive potential?","volume":"7","author":"Nixon","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1038\/s41598-021-90856-6","article-title":"Insulin micro-secretion in Type 1 diabetes and related microRNA profiles","volume":"11","author":"Januszewski","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"bbac537","DOI":"10.1093\/bib\/bbac537","article-title":"Incomplete time-series gene expression in integrative study for islet autoimmunity prediction","volume":"24","author":"Cheng","year":"2023","journal-title":"Brief. Bioinform."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1158\/1078-0432.CCR-22-1664","article-title":"Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy","volume":"28","author":"Hassel","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1158\/1078-0432.CCR-22-0404","article-title":"Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade","volume":"28","author":"Johannet","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2337\/dc18-0087","article-title":"Type 1 Diabetes TrialNet Study Group. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk","volume":"41","author":"Redondo","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13073-019-0652-8","article-title":"Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach","volume":"11","author":"Khan","year":"2019","journal-title":"Genome Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2145102","DOI":"10.1080\/21645515.2022.2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis","volume":"18","author":"Cai","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2019.01.015","article-title":"Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immuno-oncology","volume":"112","author":"Heinzerling","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events, and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3748\/wjg.v26.i22.2948","article-title":"Regenerative medicine of pancreatic islets","volume":"26","author":"Arutyunyan","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Porter, J.M., Guerassimoff, L., Castiello, F.R., Charette, A., and Tabrizian, M. (2022). INGAP-Peptide Variants as a Novel Therapy for Type 1 Diabetes: Effect on Human Islet Insulin Secretion and Gene Expression. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091833"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2651790","DOI":"10.1155\/2022\/2651790","article-title":"The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.isci.2020.101580","article-title":"Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade","volume":"23","author":"Hu","year":"2020","journal-title":"iScience"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1039\/D1CB00082A","article-title":"Enabling the next steps in cancer immunotherapy: From antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry","volume":"3","author":"Thoreau","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1159\/000516671","article-title":"The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer","volume":"99","author":"Jacobi","year":"2021","journal-title":"Oncology"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Shahid, R.K., Ahmed, S., Le, D., and Yadav, S. (2021). Diabetes and Cancer: Risk, Challenges, Management and Outcomes. Cancers, 13.","DOI":"10.3390\/cancers13225735"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:20:25Z","timestamp":1760124025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":158,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24087630"],"URL":"https:\/\/doi.org\/10.3390\/ijms24087630","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}